{"url_path":"/sec/maia/proxy/2026-04-27/000149315226019015","section_key":"body","section_title":"DEFA14A body","topic":"sec","document":{"doc_type":"DEFA14A","doc_date":"2026-04-27","source_url":"https://www.sec.gov/Archives/edgar/data/1878313/0001493152-26-019015-index.html","accession_number":"0001493152-26-019015","cik":"0001878313","ticker":"MAIA","issuer_name":"MAIA Biotechnology, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1878313/0001493152-26-019015-index.html","primary_entity_key":"0001878313","primary_entity_name":"MAIA Biotechnology, Inc."},"word_count":536,"has_tables":true,"body_markdown":"DEFA14A\n1\nformdefa14a.htm\nDEFA14A\n\n**UNITED\nSTATES**\n\n**SECURITIES\nAND EXCHANGE COMMISSION**\n\n**Washington,\nD.C. 20549**\n\n**SCHEDULE\n14A**\n\nProxy\nStatement Pursuant to Section 14(a) of\n\nthe\nSecurities Exchange Act of 1934\n\nFiled\nby the Registrant ☒\n\nFiled\nby a Party other than the Registrant\n\nCheck\nthe appropriate box:\n\n☐\nPreliminary\nProxy Statement\n\n☐\nConfidential,\nfor Use of the Commission Only (as permitted by Rule 14a-6(e)(2))\n\n☐\nDefinitive\nProxy Statement\n\n☒\nDefinitive\nAdditional Materials\n\n☐\nSoliciting\nMaterial under §240.14a-12\n\n**MAIA\nBiotechnology, Inc.**\n\n(Name\nof Registrant as Specified In Its Charter)\n\n(Name\nof Person(s) Filing Proxy Statement, if other than the Registrant)\n\n**Payment\nof Filing Fee (Check all boxes that apply):**\n\n☒\nNo\nfee required\n\n☐\nFee\npaid previously with preliminary materials.\n\n☐\nFee\ncomputed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a- 6(i)(1) and 0-11\n\n**MAIA\nBiotechnology, Inc.**\n\n**Amendment\nand Supplement to the Proxy Statement**\n\n**For\nthe Annual Meeting of Stockholders**\n\n**To\nbe Held on May 21, 2026**\n\n**EXPLANATORY\nNOTE**\n\nOn\nApril 7, 2026, MAIA Biotechnology, Inc. (“MAIA” or the “Company”) filed its definitive proxy statement (the\n“Proxy Statement”) with the Securities and Exchange Commission (“SEC”) for its annual meeting of shareholders\nto be held on May 21, 2026 (the “Annual Meeting”).\n\nThe\nCompany is amending and supplementing the Proxy Statement with the information provided in this amendment and supplement to the Proxy\nStatement (the “Amendment and Supplement”) to include information related to “Securities Authorized for Issuance Under\nEquity Compensation Plans” which was inadvertently omitted from the Proxy Statement.\n\n**Any\nproxies submitted by stockholders before the date of this Amendment and Supplement will be voted as instructed on those proxies, unless\na stockholder changes his or her vote by submitting a later dated proxy. Stockholders should follow the instructions described in the\nProxy Statement regarding how to submit proxies or vote at the Annual Meeting.**\n\n**THIS\nAMENDMENT AND SUPPLEMENT SHOULD BE READ IN CONJUNCTION WITH THE PROXY STATEMENT.**\n\n*This\nsupplemental information should be read in conjunction with the Proxy Statement, which should be read in its entirety. Section references\nin the below disclosures are to sections in the Proxy Statement, and defined terms used but not defined herein have the meanings set\nforth in the Proxy Statement. To the extent the following information differs from or conflicts with the information contained in the\nProxy Statement, the information set forth below shall be deemed to supersede the respective information in the Proxy Statement.*\n\n**Amendments\nand Supplemental Disclosure**\n\n**Proxy\nStatement**\n\nThe\ntable below entitled “Securities Authorized for Issuance Under Equity Compensation Plans” is inserted into the Proxy Statement\nimmediately following the section entitled “SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT”: as follows:\n\n**Securities\nAuthorized for Issuance Under Equity Compensation Plans**\n\nThe\nfollowing table summarizes information about our equity compensation plans as of December 31, 2025.\n\nPlan Category\n\n**Number\nof**\n\n**securities\nto**\n\n**be\nissued upon**\n\n**exercise**\n\n**of\noutstanding**\n\n**options,**\n\n**warrants\nand**\n\n**rights**\n\n**(a)**\n\n**Weighted**\n\n**average**\n\n**exercise\nprice of**\n\n**outstanding**\n\n**options,**\n\n**warrants\nand**\n\n**rights**\n\n**Number\nof**\n\n**securities**\n\n**remaining**\n\n**available\nfor future**\n\n**issuance\nunder**\n\n**equity**\n\n**compensation\nplans**\n\n**(excluding**\n\n**securities\nreflected**\n\n**in**\n\n**column\n(a))**\n\nEquity compensation plans approved\nby security holder\n25,964.601\n$2.05\n431,153\n\nEquity compensation plans not approved by security\nholder\n\n-\n\n-\n\n-\n\nTotal\n25,964,601\n$2.05\n431,153\n\n-2-"}